Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA

Vaxart, Inc.

Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.
Next trial portion will enroll 10,000 participants comparing Vaxart's KP.2 oral vaccine against an mRNA KP.2 comparator.
Sentinel cohort of 400 (XBB vs mRNA XBB) completed; DSMB recommended proceed without modification.
Vaxart awaiting BARDA approval to commence dosing in the KP.2 portion.
Funding increase supports manufacturing of new KP.2 lots and expanded clinical activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.